Search

Search Results

• Role of sodium-glucose cotransporter 2 inhibitors in cardiovascular events in patients with heart failure

  Eva Muja, Letizia Giuseppina Floccari, Artan Simaku, Klodeta Grosha, Besim Lama, Ilirian Laçi

  22-07-2025

  https://doi.org/10.4081/itjm.2025.1997

  717

  PDF: 353

  HTML: 50

• Sodium-glucose cotransporter 2 inhibition in patients with liver cirrhosis and diabetes: a possible role in ascites control?

  Aurelio Seidita, Francesca Mandreucci, Mirco Pistone, Silvia Calderone, Alessandra Giuliano, Marta Chiavetta, Lydia Giannitrapani, Roberto Citarrella, Maurizio Soresi, Anna Licata, Antonio Carroccio, Stella Compagnoni

  12-11-2024

  https://doi.org/10.4081/itjm.2024.1829

  2304

  PDF: 727

  SUPPLEMENTARY MATERIAL: 348

  HTML: 112

• Sodium-glucose co-transporter-2 inhibitor-associated non-diabetic ketoacidosis: a case report

  Vincenzo Trapanese, Francesco Maruca, Maria Resilde Natale, Federica Giofrè, Francesca Cosentino, Silvia Sergi, Giuseppe Armentaro, Valentino Condoleo, Franco Arturi

  04-04-2024

  https://doi.org/10.4081/itjm.2024.1716

  1311

  PDF: 784

  HTML: 284
• 

  The management of heart failure: a FADOI survey in the setting of Internal Medicine Units

  Fernando Gallucci

  16-02-2023

  https://doi.org/10.4081/itjm.2023.1573

  2287

  PDF: 719

  HTML: 13

• ORAL COMMUNICATION | Semaglutide plus empagliflozin improves renal outcomes compared with monotherapies in type 2 diabetes: a real-world study

  P. Villari, A. M. Labate

  22-05-2026

  https://doi.org/10.4081/itjm.2026.2593

  171

  PDF: 88

• P127 | Dapagliflozin and acute pancreatitis: a case report F. Pugliese, R. Falzone, L. Lenzi, M. Pizzini, S. Cozzio | Internal Medicine S. Maria del Carmine Rovereto, APSS Trento, Italy

  27-08-2025

  https://doi.org/10.4081/itjm.2025.2323

  313